The expression of the steroidogenic acute regulatory protein (StAR) in the human corpus luteum (CL) was examined throughout the luteal phase. The primary 1.6-kb StAR transcript was in greater abundance in early (3.1-fold) and mid (2.2-fold) luteal phase CL compared with late luteal phase CL. 
P ROGESTERONE DERIVED from the corpus luteum (CL) is required for the development of a receptive endometrium and for the maintenance of early gestation. During the menstrual cycle, CL development and steroidogenesis are dependent on pituitary-derived LH (1) . During the cycle of conception, the CL is rescued by trophoblastic production of hCG. LH and hCG bind to and activate a specific glycoprotein LH/hCG membrane receptor on luteal cells that regulates genes essential for steroid biosynthesis. The action of LH/hCG on luteal cells is mediated predominantly by the cAMP second messenger system (2) . However, a variety of growth factors and cytokines, including IL-1␤ (3), TNF␣ (4), insulin, IGF-I (5, 6), and IGF-binding proteins (7) , modulate the action of LH on steroidogenesis. The level of progesterone production is determined by several factors, including the uptake of lipoprotein-carried cholesterol, cholesterol translocation to the inner mitochondrial membrane, and expression and activity of cytochrome P450 side-chain cleavage and 3␤-hydroxysteroid dehydrogenase, the enzymes involved in the conversion of cholesterol to progesterone (8) . The ratelimiting step in progesterone synthesis appears to be movement of cholesterol from the outer to the inner mitochondrial membrane where the cytochrome P450 sidechain cleavage system is located (8) . Steroidogenic acute regulatory protein (StAR), a phosphoprotein expressed in steroidogenic cells, is essential for this sterol translocation process (9) . Human granulosa cells, which contain low concentrations of StAR before the ovulatory surge of LH, acquire large amounts of StAR during luteinization (10) . There is limited information regarding the expression of StAR in human CL throughout the luteal phase (11, 12) . In the present study we examined StAR mRNA expression, protein levels, and the immunolocalization of StAR in granulosa-lutein and thecal-lutein cells in CL of different ages. We hypothesized that StAR mRNA expression and protein levels are regulated within the CL throughout the luteal phase, playing a key role in controlling luteal progesterone production during the development and demise of the CL.
Abbreviations: CL, Corpus luteum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; StAR, steroidogenic acute regulatory protein.
Subjects and Methods Subjects
CL were enucleated at the time of minilaparotomy from 20 women undergoing tubal ligation. All subjects gave informed consent to participate in this study. The surgery was scheduled at varying times throughout the luteal phase at the Hospital Clinico San Borja Arriarán, National Health Service, University of Chile (Santiago, Chile). All women were healthy, aged 33-42 yr, with normal body mass index, and regular menstrual cycles, and they had not received any form of hormonal treatment for at least 3 months before participating in the study. Blood was collected before surgery for steroid determinations. Three women undergoing tubal ligation were administered Cetrorelix (2 mg, sc; ASTA Medica AWD GmnH, Frankfurt, Germany) during the midluteal phase 24 h before surgery. Plasma LH and progesterone were determined by specific RIA as previously reported (5) . These studies were approved by the internal review board of the Hospital Clinico San Borja Arriarán.
Dating of the CL
The CL were dated on the basis of the presumptive day of ovulation (d 0), which was determined by serial urinary LH measurements or serial vaginal ultrasound images of the ovaries and was confirmed by the histological dating of an endometrial biopsy. Additionally, plasma progesterone levels and the histological features of each CL were used to confirm tissue dating. The principal light microscopic criteria used in determining the age of the CL included the sprouting of capillaries into the granulosa cells, the luteinization of granulosa cells, the prominent morphological difference between thecal-lutein and granulosa-lutein layers, the appearance of fibroblasts in the central cavity, and shrinkage and vacuolization of the granulosa cells (13) . The CL were classified as early (4 d postovulation; n ϭ 4), mid (5-10 d postovulation; n ϭ 7), and late (Ͼ11 d of ovulation; n ϭ 6).
The entire CL was enucleated from the ovary and immediately transported under sterile conditions to the laboratory. The CL was washed with cold NaCl (0.9%) solution to remove blood clots and immediately divided into radial blocks. Tissue for histology and immunohistochemistry was fixed in 4% buffered paraformaldehyde and embedded in paraffin wax. Other pieces were snap-frozen in liquid nitrogen and stored at Ϫ70 C for subsequent RNA and protein extraction.
Northern blot analysis
Total RNA was prepared as described by Chomczynski and Sacchi (14) and quantified by absorbance at 260 nm. Northern analysis was carried out using the StAR cDNA as a probe (10) . Briefly, 10 g total RNA were resolved on 1% agarose-formaldehyde gels, blotted onto a GeneScreen Plus nylon membrane (NEN Life Science Products, Boston, MA), and cross-linked by UV irradiation. The membranes were prehybridized for 30 min at 42 C in ULTRAhyb hybridization solution (Ambion, Inc., Austin, TX). Hybridization was carried out overnight at 42 C in the same solution after addition of the 32 P-labeled probe (10 6 cpm/ml solution). Membranes were washed twice for 5 min each time at 42 C in 0.5 ϫ SSC/0.1% SDS, followed by two washes in 0.1 ϫ SSC/0.1% SDS for 15 min each time at 42 C. Blots were exposed to x-ray film for 24 h. StAR signals were normalized for loading differences with the densitometric values obtained for 28S rRNA ethidium staining. Intensities of autoradiographic signals/ethidium staining were estimated by densitometric scanning using a BioImage Scanner UMAX VistaScan T630 (BioImage, Ann Arbor, MI; software NIH 1.6).
Quantitative real-time RT-PCR
Total RNA (5 g) from patients (n ϭ 2) at each stage of the luteal phase was treated with RQ1-ribonculease-free deoxyribonuclease (Promega Corp., Madison, WI) for 30 min at 37 C before RT with Moloney murine leukemia virus reverse transcriptase (Promega Corp.) as described by the manufacturer. The resulting cDNA were subjected to quantitative real-time PCR. The forward (CCACCCCTAGCACGTGGAT) and reverse (TCCTGGTCACTGTAGAGAGTCTCTTC) primers and probe (CGGAGCTCTCTACTCGGTTCTCGGC) were designed to span an intronic splice site (intron 5) with the Primer Express software package that accompanies the PE Applied Biosystems 7700 sequence detector (PerkinElmer Corp., Foster City, CA). The real-time PCR used 900 nm of each primer, 200 nm probe, and the TaqMan Universal Master Mix (PE Applied Biosystems). Agarose gel electrophoresis indicated the presence of a single PCR product. To account for differences in starting material the human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers and probe reagents from PE Applied Biosystems were used as described by the manufacturer. The experimental and GAPDH PCR reactions were performed in separate tubes in triplicate, and the average threshold cycle for the triplicate was used in all subsequent calculations. The coefficient of variation among the triplicates for the StAR and GAPDH PCR reactions were 0.52 Ϯ 0.19% and 0.50 Ϯ 0.20%, respectively.
Western blot analysis
Luteal tissues were homogenized in a buffer containing 20 mm HEPES, 100 mm KCl, 1 mm dithiothreitol, 2 mm EDTA, 0.2 mm phenylmethylsulfonylfluoride, and 50 mm benzamidine and centrifuged at 10,000 ϫ g for 15 min. The supernatant was recovered and used for Western blotting. Protein concentrations were determined by the BioRad Laboratories, Inc., dye-binding assay. Five micrograms of protein extract were loaded onto 10% SDS-PAGE gels for electrophoresis. After electrophoresis, proteins were transferred to polyvinylidene difluoride membranes (Hybridon, Millipore Corp., Bedford, MA). The membranes were incubated with a rabbit polyclonal antihuman StAR antibody as previously described (15) . The antirabbit Vistra ECF Western blotting kit (Amersham Pharmacia Biotech, Arlington Heights, IL) was used to detect the primary antibody and generate a chemifluorescence signal that was quantified on a Storm Phosphor Imager (Molecular Dynamics, Sunnyvale, CA) using the blue fluorescence/chemifluorescence mode. ImageQuant 1.1 software (Molecular Dynamics, Inc.) was used to analyze the signals for both preprotein and mature StAR protein.
Immunohistochemical localization of StAR in human CL
Tissue sections (5 m) of early (n ϭ 4), mid (n ϭ 4), and late CL (n ϭ 4) luteal phases and placenta were mounted on ProbeOn Plus slides (Fisher Scientific, Pittsburgh, PA) and deparaffinized with a xylol substitute solvent (Poly/clear solvent, DAKO Corp., Carpinteria, CA) as previously reported (16) . The sections were stained by the peroxidase conjugate technique (Calbiochem-Novabiochem Co., La Jolla, CA) using capillary technology (FisherBiotech MicroProbe Staining System). Briefly, these sections were incubated in 3% H 2 O 2 to block endogenous peroxidase activity. Nonspecific binding was suppressed with normal goat serum diluted 1:10 in PBS containing 4% BSA. The sections were incubated with a rabbit polyclonal anti-StAR antibody at a dilution of 1:500. After three washes in PBS, the sections were incubated with a goat antirabbit IgG-peroxidase conjugate diluted 1:2000. Color was developed with 3,3Ј-diaminobenzidine tetrahydrochloride (DAKO Corp.). The sections were counterstained with Mayer's hematoxylin solution (DAKO Corp.).
Incubation with normal rabbit serum in place of anti-StAR antibody served as a negative control, as did staining of placental tissue, which does not express StAR. Slides were evaluated by two observers using a subjective semiquantitative scale of 0 for no staining, ϩ for minimal staining, 2ϩ for moderate staining, and 2ϩϩ for intense staining.
Statistical analysis
Northern and Western blotting experiments performed with CL tissue included at least four subjects for each stage of the luteal phase. All data were analyzed by ANOVA. Differences among individual means were tested using t tests. P Ͻ 0.05 was considered statistically significant. The relationship between StAR protein level and plasma progesterone concentrations was determined by linear regression analysis (␣ ϭ 0.05). Table 1 presents the clinical characteristics of the subjects, including plasma progesterone and 17␤-E2 concentrations for the different stages of the luteal phase and after GnRH antagonist treatment. There were no differences in mean age and BMI of the subjects between the groups. The mean weight of the CL was significantly greater during the early and midluteal phases compared with the late luteal phase. Treatment of women with Cetrorelix caused a pronounced decline in CL weight compared with the control midluteal phase CL. Levels of progesterone and E2 at the time of surgery were greater (P Ͻ 0.05) in the early and midluteal phases than those measured during the late luteal phase or after Cetrorelix treatment.
Results
A representative Northern blot for StAR expression is shown in Fig. 1A . The 1.6-kb transcript was most abundant in CL throughout the luteal phase. The 4.4-kb StAR transcript was most abundant in midluteal phase CL, with smaller amounts found in early CL, whereas none was detected in late CL. Figure 1B illustrates the densitometric analysis of StAR mRNA (1.6-kb transcript) levels in human CL, which revealed that the relative abundance was 3.1-fold greater in early phase CL and 2.2-fold greater in midluteal phase CL compared with late CL (P Ͻ 0.05). Real-time quantitative RT-PCR results were similar to the Northern data, with early and midluteal phase CL exhibiting 2.87 Ϯ 0.19-and 2.68 Ϯ 0.13-fold more StAR mRNA than that observed in late CL. Figure 2A depicts a representative Western blot for StAR proteins in luteal tissues of different ages. The blot shows immunoreactive bands at 37 and 30 kDa that represent the StAR preprotein and the mature StAR protein, respectively. The 30-kDa StAR protein was most abundant in early and midluteal phase CL and was diminished in late CL extracts. The StAR preprotein (37 kDa) was visualized in early and midluteal CL and to a lesser extent in late CL. The relative abundance of the 30-kDa species was 2.5-fold greater in early CL and 3-fold greater in mid CL compared with late CL (P Ͻ 0.05; Fig. 2B ). The relationship between the amount of StAR 30-and 37-kDa proteins in CL expressed as relative units and the plasma concentration of progesterone (nanomoles per liter) from 13 subjects is depicted in Fig. 4 . The high correlation coefficients (r ϭ 0.73 and r ϭ 0.79) for the StAR preprotein and the mature protein, respectively, suggest an association between the abundance of StAR protein within the CL and its steroidogenic capacity throughout the luteal phase.
Cetrorelix administered during the midluteal phase caused a marked decline in plasma LH levels within 2 h after administration (P Ͻ 0.05). Mean plasma progesterone concentrations declined by more than 50% within 6 h after Cetrorelix administration and remained suppressed for 24 h (P Ͻ 0.05). Northern blot analysis demonstrated a loss of the 4.4-kb StAR mRNA by 24 h after Cetrorelix treatment. The 1.6-kb StAR transcript was also reduced by approximately 50%. The levels of the mature 30-kDa StAR protein declined modestly after Cetrorelix administration, but surprisingly there was no effect of Cetrorelix treatment on the 37-kDa StAR preprotein levels (Fig. 5C ).
Discussion
The human CL is a remarkable steroidogenic gland that produces up to 40 mg progesterone daily, reflecting a highly efficient steroidogenic machinery. It is known that StAR plays a key role in the steroidogenic process (17) . StAR mRNA and protein expressions have been detected in CL of several species, including the bovine (18), ovine (19) , rabbit (20) , and equine (21) . Our laboratory previously demonstrated that StAR mRNA and protein are expressed in the human CL (10, 16) . The present study extends our earlier observations to include the appraisal of StAR gene expression, protein levels, and immunohistochemical localization of StAR within the steroidogenic cells of the CL throughout the luteal phase. It is well accepted that StAR is responsible for translocation of cholesterol from the outer to the inner mitochondrial membrane, the rate-limiting step in steroid hormone production (22) . Thus, to better understand the significant steroidogenic changes that occur during the human luteal phase, it was important to define StAR gene expression and protein levels within the CL.
Our data confirm the recent findings of Chung et al. (11) and Duncan et al. (12) , which indicate that the 1.6-kb transcript is the dominant StAR mRNA expressed in the human CL throughout the luteal phase. However, the pattern for StAR gene expression determined in the present study differs from that reported by these investigators. Our Northern and quantitative RT-PCR results illustrate that the StAR mRNA is most abundant during the early and midluteal phases and declines significantly in late luteal phase CL. In contrast, Chung et al. (11) found that expression of the 1.6-kb transcript was more abundant in early luteal phase CL, followed by a significant decrease in the mid and late luteal phase CL. On the other hand, Duncan et al. (12) reported that StAR mRNA abundance did not change throughout the luteal phase. These discrepancies might be explained by lack of precision in dating the stage of the luteal phase or heterogeneity of the subjects studied, including the impact of gynecological disease.
We detected a less abundant 4.4-kb transcript in early and mid CL. The 1.6-and 4.4-kb StAR transcripts vary in the length of the 3Ј-untranslated region, and both increase in response to tropic stimulation with different kinetics (8) . It is interesting to note that the 4.4-kb transcript exhibited a greater response to 8-bromo-cAMP in proliferating human thecal cells (10) than proliferating human granulosa cells (15) . However, the biological significance of these two transcripts is not known at this time.
To our knowledge this is the first report of the simultaneous assessment of StAR mRNA expression and protein levels in human CL of different ages. Western blot analysis indicated that the mature StAR (30-kDa) mitochondrial protein was the most abundant species within the CL throughout the luteal phase. Mature StAR protein decreased significantly during the late luteal phase, following the pattern of StAR mRNA. The levels of the 37-kDa preprotein changed in a similar pattern. Thus, changes in StAR mRNA, presumably determined by rates of StAR gene transcription, appear to control StAR protein levels. Moreover, in the present investigation we found a high correlation coefficient between the 30-kDa StAR protein and the 37-kDa StAR preprotein within the CL and the plasma concentrations of progesterone. This correlation is consistent with the hypothesis that StAR protein plays a key role in regulating luteal progesterone output.
Administration of GnRH antagonist resulted in a marked decline in LH, and with the fall in LH there was the expected reduction in progesterone levels (23, 24) . The reduction in LH resulted in the complete loss of the 4.4-kb StAR transcript and a substantial decline in the 1.6-kb transcript. This pattern of StAR mRNA expression is similar to that found in the late luteal phase CL. Mature StAR protein was also reduced in luteal tissue from women receiving Cetrorelix. Interestingly, the level of the 37-kDa StAR preprotein did not appear to be similarly affected. The latter unexpected finding contrasts with the declining StAR mRNA and mature StAR protein levels. The 37-kDa preprotein is thought to be the active form of StAR, so the maintenance of preprotein levels in the face of declining progesterone levels is enigmatic. One possible explanation is that the phosphorylation state of StAR preprotein may be a critical determinant of StAR activity. StAR is phosphorylated by PKA in a cAMP-dependent manner (25) . Thus, the Cetrorelix-induced fall in LH may have prevented StAR preprotein phosphorylation, diminishing StAR's functional activity, resulting in reduced steroid output from the CL without a dramatic change in preprotein levels. Another possibility is that the loss of LH may have caused a reduction in the movement of StAR protein into the mitochondria, thus preventing the processing of StAR and resulting in a build-up of the preprotein. Alternatively, the decline in luteal progesterone production resulting from the Cetrorelix-induced LH withdrawal may be due to additional factors, including a reduced activity of other LH-dependent processes required for steroidogenesis (e.g. cholesterol esterase activity, lipoprotein-mediated cholesterol uptake, cholesterol transport to mitochondria).
We also assessed by immunohistochemistry the cellular localization of the StAR protein within the CL throughout the luteal phase. Our current findings agree with our previously described localization of StAR in the human CL, indicating that StAR is expressed in both thecal-and granulosa-lutein cells (10, 16) . We found that StAR staining intensity was greatest in thecal-lutein cells of the CL regardless of the stage of the luteal phase. The more intense staining of the thecallutein cells may reflect their smaller volume compared with the larger granulosa-lutein cells. It could also reflect a higher level of gene expression. This would be concordant with the greater steroidogenic responsiveness of enriched small luteal cells and their significantly greater specific binding capacity for [
125 I]hCG compared with large luteal cells (26) . StAR immunostaining in granulosa-lutein cells was heterogeneous within the CL. Numerous intensely stained cells were interspersed among others that were only lightly stained. This pattern was observed in CL of all ages. Additionally, the granulosa-lutein cells close to the central cavity from mid CL exhibited the most intense staining. This interesting regional distribution is evidence for intraluteal control of StAR gene expression, possibly as a result of paracrine factors such as IGF-I, which is expressed in CL (5) and stimulates StAR expression (15, 27) .
The underlying mechanisms controlling the diminished StAR gene and protein expression during luteal regression could not be determined in this study. However, several possible explanations can be suggested for the diminished levels of StAR mRNA and protein. It was recently noted by our group that IL-1␤ and nitric oxide inhibit progesterone synthesis by human luteal cells (3, 28) . Cytokines have an inhibitory action on StAR gene and protein expression (29) .
In vitro experiments show that luteal leukocytes secrete high levels of cytokines that inhibit hCG-stimulated progesterone production (3, 4) . Furthermore, TNF␣ may affect StAR gene expression by suppressing transcription (29) . Hence, intraluteal factors may control the production of StAR and, consequently, the steroidogenic activity of the CL.
